Antibody · 폐암 (NSCLC) · VEGF

Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

AntibodystaleThe First Affiliated Hospital o…Phase 2

Adebrelimab Combined with Bevacizumab and Docetaxel (Adebrelimab Combined with Bevacizumab and Docetaxel)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-Small-CellLungCarcinoma#Antibody#Phase2#항체#면역항체+2

Belinostat, carboplatin, paclitaxel and bevacizumab (Belinostat, carboplatin, paclitaxel and bevacizumab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

임상시험 1상태 DISCONTINUED

AntibodystaleXinqiao Hospital of ChongqingPhase 2

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

NSCLC Stage IV Without EGFR/ALK Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4

AntibodystaleCentre Francois BaclessePhase 2

atezolizumab (Tecentriq, Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab)

NSCLC Stage IIIB; NSCLC Stage IV · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4

효능 ORR 42.9%임상시험 1상태 ACTIVE

AntibodystaleImmunityBio, Inc.Phase 3

atezolizumab (Tecentriq, Carboplatin and paclitaxel plus atezolizumab and bevacizumab.)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 DISCONTINUED

AntibodystaleDizal PharmaceuticalsPhase 2

DZD9008 plus Bevacizumab (DZD9008 plus Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2

Docetaxel/Carboplatin/Bevacizumab/Erlotinib (Docetaxel/Carboplatin/Bevacizumab/Erlotinib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

AntibodystaleNational Cancer Center, KoreaPhase 2

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

EGFR Positive Non-small Cell Lung Cancer · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3

Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab (Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

AntibodystaleHunan Province Tumor HospitalPhase 2

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2

AntibodystaleRochePhase 3

Bevacizumab Biosimilar Drug (MB02, MB02 (Bevacizumab Biosimilar Drug))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase3#항체#면역항체+2

효능 ORR 40.3%임상시험 1상태 ACTIVE

AntibodystaleSe-Hoon LeePhase 2

Olaparib+Bevacizumab to SCLC patients (Olaparib+Bevacizumab to SCLC patients)

Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+2

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3

QLS5132; Bevacizumab (QLS5132; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3

QLS5132; Olaparib; Bevacizumab (QLS5132; Olaparib; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3

QLS5132; Platinum; Bevacizumab (QLS5132; Platinum; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

AntibodystaleRochePhase 3

Serplulimab combined with bevacizumab and first-line chemotherapy (Serplulimab combined with bevacizumab and first-line chemotherapy)

Non-small Cell Lung Cancer Stage II; Bevacizumab · Non-small Cell Lung Cancer Stage II

#Non-smallCellLungCancerStageII#Antibody#Phase3#항체#면역항체+3